First-Time CEOs: Firsthand Tales Of The Good, The Bad, And The Ugly

Being a first-time life science industry CEO is no cake walk. There’s the endless need to find funding. There’s the ongoing challenge of selling the science. But what else? What is the good, the bad, and the ugly of being a first-time biopharma CEO? More importantly, what are some of the best business practices learned from those that have “been there, done that?”

Life Science Leader’s first live executive virtual roundtable featured Roger Crystal, M.D., CEO, Opiant Pharmaceuticals; Frank Lee, CEO, Forma Therapeutics; and Ivana Magovcevic-Liebisch, Ph.D., J.D., CEO, Vigil Neuroscience. During the live event held on June 16, 2021, attendees had the opportunity to pose their own questions to panel participants.